Find Clinical Trial

Early treatment of Idiopathic Parkinson’s Disease (IPD) with dopaminergic agonist piribedil in monotherapy (adaptation of the daily dose from 150 to 300 mg per day per os). A 2-year randomised, parallel group, placebo controlled study in IPD “de novo” patients.


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationParkinson's disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

PIRIBEDIL,
S004200

Active Substance CodeS004200
Protocol CodeCL3-04200-006
ISRCTN CodeISRCTN36646813


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility